Skip to content

Long-term Study of SJP-0132 in Patients with Dry Eye Disease

SJP-0132 Phase 3 -Multicenter, Open-label, Long-term Study in Patients with Dry Eye Disease-

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2031220392
Enrollment
150
Registered
2022-12-08
Start date
2023-01-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Disease

Interventions

Administer SJP-0132 as an eye drop to participants with dry eye disease

Sponsors

Omatsu Kazunori
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Aged over 18 years at the time of the informed consent (any gender) - Live in Japan - Have continuous subjective symptoms of dry eye disease - Tear film break-up time of <= 5 seconds - Meet the other protocol-specified inclusion criteria may apply

Exclusion criteria

Exclusion criteria: - Unable to discontinue wearing contact lens during the study - Have a history of, or scheduled corneal transplantation during the study - Have a history of, or scheduled permanent punctal occlusion during the study - Have used or anticipates use of a punctal plug during the study - Have a history of, or scheduled ocular surface surgery during the study - Have ophthalmic disease other than dry eye disease - Have disease that affects subjective symptoms of dry eye - Have known history of hypersensitivity or serious adverse reaction to any of the study drug ingredients - Unable to discontinue any ophthalmic medicines including OTC, except test drug for ophthalmic examination during the study - Female participant who is pregnant, potentially pregnant, lactating or intents to become pregnant. And unable to obtain a consent to practice adequate contraception during the study - Male participant who does not agree to practice adequate contraception and not to donate sperm during the study - Have judged that it is inappropriate to participate in this study by investigator - Meet the other protocol-specified exclusion criteria

Design outcomes

Primary

MeasureTime frame
Safety

Secondary

MeasureTime frame
Dry eye signs and symptoms

Contacts

Public Contactdivision Clinical

Senju Pharmaceutical Co., Ltd.

senju-clinicaltrials@senju.co.jp+81-78-777-1018

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026